The introduction of the BIOSECURE Act marks a significant moment in U.S. legislative history, specifically targeting the intersection of national security and biotechnology. This proposed legislation aims to halt federal contracts with Chinese biotech firms, citing potential national security
The proposed BIOSECURE Act stands poised to significantly alter the landscape of U.S.-China biopharma partnerships by addressing national security concerns through restrictive measures. Specifically, the act aims to block certain Chinese biotech equipment and service providers from the U.S. market.
Optimizing cell line development (CLD) for next-generation biologics is crucial to meet the rapidly growing demand for novel therapeutic modalities. As the biologics sector evolves, it's imperative to address potential bottlenecks in the development process through strategic enhancements and
Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.
The Cell Banking Outsourcing Market is on the brink of a significant upswing, with projections estimating a surge from a robust USD 11.03 billion in 2022 to a staggering USD 33.12 billion by 2029. This exponential growth, driven by an impressive Compound Annual Growth Rate (CAGR) of 17.01%,
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
